Author Archive

BPC July 13 updates: RARE Phase 3 data due TODAY. MNOV interim Phase 2b MS analysis due 4Q + LOXO update

Jul 14, 2016 No Comments

Updates to the Company Pipeline Database for July 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary LOXO 26.57 LOXO-101 Solid tumors that harbor a TRK fusion. Phase 2 Phase 2 basket trial initiated October 2015. Enrolment update due 2H 2016 MNOV 7.03 MN-166 Progressive multiple sclerosis (progressive MS) Phase […]

Read more

BPC July 12 updates: SAGE hits Phase 2 endpoint. JUNO clinical hold lifted + updates for ITEK AVIR

Jul 13, 2016 2 Comments

Updates to the Company Pipeline Database for July 12, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AVIR 1.25 BTA585 Respiratory syncytial virus (RSV) infections Phase 2a Phase 2a enrolment resumed July 2016. Trial to be completed by end of 2016 ITEK 8.51 Trabodenoson and latanoprost Glaucoma Phase 2 Phase […]

Read more

BPC July 11 updates: CYTR tumbles on poor data. SCMP discontinues Cobiprostone program + updates for ACST CHRS CLDX CYTR MYOK

Jul 11, 2016 No Comments

Updates to the Company Pipeline Database for July 11, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACST 1.33 CaPre (TRIFECTA trial) Hypertriglyceridemia Phase 2 Phase 3 planned CHRS 21.93 CHS-1701 Pegfilgrastim biosimilar BLA filing BLA to filed 3Q 2016 CLDX 4.57 CDX-014 Renal cell carcinoma (RCC) – cancer Phase […]

Read more

BPC July 7 updates: Clinical hold placed on JUNO -JCAR015. KITE still on track for Phase 2 ZUMA-1 data + BLA filing 2H 2016. TXMD NDA filing + updates for ALNY CTIX MCRB NVLS PLX

Jul 08, 2016 No Comments

Updates to the Company Pipeline Database for July 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ALNY 61.52 ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017 CTIX 1.28 Prurisol Placque psoriasis Phase 2b Phase 2b trial to be […]

Read more

BPC July 5 updates: INSY FDA Approval. CANF fails to meet Phase 2 primary endpoint. CEMP PDUFA date set for late December + updates for IPCI PRTA RGNX

Jul 06, 2016 No Comments

Updates to the Company Pipeline Database for July 6, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary CANF 2.11 CF101 Glaucoma Phase 2 Phase 2 failed to meet endpoint – July 2016 CEMP 16.93 Solithera – oral Community-acquired bacterial pneumonia (CABP) PDUFA PDUFA December 27 2016 CEMP 16.93 Solithera – […]

Read more

BPC July 1 updates: FDA determines that PTIE DRRX Advisory Committee Meeting is NOT required + ALNY XBIT AEZS updates

Jul 02, 2016 No Comments

Updates to the Company Pipeline Database for July 1, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AEZS 3.61 Zoptrex Castration and taxane resistant prostate cancer Phase 3 Phase 3 trial to be completed 3Q 2016 ALNY 61.44 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 […]

Read more

BPC updates June 30: ARRY Binimetinib NDA filing. AMPE fails to meet Phase 3 endpoints. CYNA Phase 3 data now due end of 3Q + updates for ARQL CYTK ITCI NDRM

Jul 01, 2016 No Comments

Updates to the Company Pipeline Database for June 30, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AMPE 1.29 Ampion Osteoarthritis of the Knee Phase 3 STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint – June 2016 ARQL 1.90 […]

Read more

BPC updates June 29: Poles apart – TSRO soars over 100% while GALE crashes over 80% on data releases. LPCN issued CRL + updates for ATNM BPMX CARA GBT

Jun 29, 2016 No Comments

Updates to the Company Pipeline Database for June 29, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ATNM 1.77 Iomab-B Hematopoietic Stem Cells Transplantation Phase 2 Phase 3 to be initiated June 2016 BPMX 0.66 BPX-01 Acne Phase 2a Phase 2a top-line data released June 2016. Phase 2b to be […]

Read more

BPC June 28 updates: ANTH CYAD ESPR fall on disappointing updates. EGLT Advisory Committee Meeting August 4 + updates for ACRX BLRX CHRS EARS INFI ITCI KTOV MRNS NDRM RARE XNCR XOMA

Jun 29, 2016 No Comments

Updates to the Company Pipeline Database for June 28, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACRX 2.50 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 top-line data due 3Q 2016, with potential NDA filing by end of 2016 ANTH 3.07 Blisibimod Lupus Phase 3 Missed primary endpoints in […]

Read more

BPC June 27 updates: MRNS data due TODAY. RGLS tumbles on news of clinical hold. AAAP PDUFA date set for December 26 + updates for PBYI MDCO TBRA

Jun 27, 2016 No Comments

Updates to the Company Pipeline Database for June 27, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AAAP 27.77 Lutathera Inoperable progressive midgut NETs PDUFA priority review PDUFA date under priority review December 28, 2016 MDCO 33.28 CARBAVANCE Complicated urinary tract infections (cUTI) NDA Filing Phase 3 data met endpoints […]

Read more

BPC June 23 updates: INNL Phase 3 data due 3Q or early 4Q. ARGL Phase 2 prelim data due June 30 + CAPR CERU RETA

Jun 24, 2016 No Comments

Updates to the Company Pipeline Database for June 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ARQL 1.92 ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 2 Phase 2 preliminary data due June 30, 2016 at ESMO 18th World Congress on Gastrointestinal Cancer CAPR 4.38 CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) […]

Read more